Belinostat
CAS No. 866323-14-0
Belinostat( PXD101 | PX105684 | PXD-101 | PXD 101 | PX-105684 )
Catalog No. M16294 CAS No. 866323-14-0
A potent HDAC inhibitor with IC50 of 27 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 58 | Get Quote |
|
| 50MG | 133 | Get Quote |
|
| 100MG | 197 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBelinostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent HDAC inhibitor with IC50 of 27 nM.
-
DescriptionA potent HDAC inhibitor with IC50 of 27 nM (HeLa cell extracts); inhibits histone deacetylase activity in cell lysates with IC50 of 9-100 nM, increases the acetylation of histone H4 and induces apoptosis in tumor cell lines; inhibits the growth of a range of human tumor cell lines in vitro (IC50=0.2-3.4 uM); shows antitumor activity in vivo with no apparent toxicity.Blood Cancer Approved.
-
In VitroBelinostat (PXD101) induces a concentration-dependent (0.2-5 μM) increase in acetylation of histone H4 in tumor cell lines. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC50s in the range 0.2-3.4 μM as determined by a clonogenic assay and induces apoptosis. Belinostat inhibits the growth of a number of human tumor cell lines in vitro with IC50s determined by a clonogenic assay in the range 0.2-3.4 μM. Belinostat (PXD101) is a potent histone deacetylase (HDAC) inhibitor, potently inhibits the enzymatic activity of purified recombinant HDAC6 (IC50 of 82 nM).
-
In VivoTreatment of nude mice bearing human ovarian and colon tumor xenografts with Belinostat (10-40 mg/kg/day i.p.) daily for 7 days causes a significant dose-dependent growth delay with no obvious signs of toxicity to the mice. Growth delay is also observed for xenografts of cisplatin-resistant ovarian tumor cells. A marked increase in acetylation of H4 is detected in blood and tumor of mice 3 h after treatment with Belinostat (PXD101). The inhibition of growth of human tumor xenografts in mice, with no apparent toxicity. Belinostat (PXD101) displays single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which is enhanced via combination therapy with Carboplatin.
-
SynonymsPXD101 | PX105684 | PXD-101 | PXD 101 | PX-105684
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number866323-14-0
-
Formula Weight318.3477
-
Molecular FormulaC15H14N2O4S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NO)/C=C/C1=CC=CC(S(=O)(NC2=CC=CC=C2)=O)=C1
-
Chemical Name2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Plumb JA, et al. Mol Cancer Ther. 2003 Aug;2(8):721-8.
2. Qian X, et al. Mol Cancer Ther. 2006 Aug;5(8):2086-95.
3. Buckley MT, et al. J Transl Med. 2007 Oct 12;5:49.
molnova catalog
related products
-
Pandacostat
Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi).
-
TYA-018
TYA-018 is an orally available and selective HDAC6 inhibitor with cardioprotective properties for the study of dilated heart disease and heart failure.TYA-018 prevents sarcomere damage and decreases Nppb expression.
-
Resminostat
A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.
Cart
sales@molnova.com